These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 38766497)

  • 1. Hepatocellular carcinoma: Advances in systemic therapies.
    Wu TK; Hui RW; Mak LY; Fung J; Seto WK; Yuen MF
    F1000Res; 2024; 13():104. PubMed ID: 38766497
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The evolution of immune checkpoint inhibitor combinations in advanced hepatocellular carcinoma - A systematic review.
    Meyers BM; Knox JJ; Liu DM; McLeod D; Ramjeesingh R; Tam VC; Lim HJ
    Cancer Treat Rev; 2023 Jul; 118():102584. PubMed ID: 37336142
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The New Era of Systemic Treatment for Hepatocellular Carcinoma: From the First Line to the Optimal Sequence.
    Cerreto M; Cardone F; Cerrito L; Stella L; Santopaolo F; Pallozzi M; Gasbarrini A; Ponziani FR
    Curr Oncol; 2023 Sep; 30(10):8774-8792. PubMed ID: 37887533
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Critical Appraisal of Guideline Recommendations on Systemic Therapies for Advanced Hepatocellular Carcinoma: A Review.
    Cappuyns S; Corbett V; Yarchoan M; Finn RS; Llovet JM
    JAMA Oncol; 2024 Mar; 10(3):395-404. PubMed ID: 37535375
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evolving therapeutic landscape of advanced hepatocellular carcinoma.
    Yang C; Zhang H; Zhang L; Zhu AX; Bernards R; Qin W; Wang C
    Nat Rev Gastroenterol Hepatol; 2023 Apr; 20(4):203-222. PubMed ID: 36369487
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Updates on Systemic Therapy for Hepatocellular Carcinoma.
    Ntellas P; Chau I
    Am Soc Clin Oncol Educ Book; 2024 Jan; 44():e430028. PubMed ID: 38175973
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Goals and targets for personalized therapy for HCC.
    Couri T; Pillai A
    Hepatol Int; 2019 Mar; 13(2):125-137. PubMed ID: 30600478
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Emerging drugs for the treatment of hepatocellular carcinoma.
    Ayoub WS; Jones PD; Yang JD; Martin P
    Expert Opin Emerg Drugs; 2022 Jun; 27(2):141-149. PubMed ID: 35642526
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systemic therapies in hepatocellular carcinoma: A revolution?
    Fortuny M; Sanduzzi-Zamparelli M; Reig M
    United European Gastroenterol J; 2024 Mar; 12(2):252-260. PubMed ID: 38267015
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evidence-Based Management of Hepatocellular Carcinoma: Systematic Review and Meta-analysis of Randomized Controlled Trials (2002-2020).
    Haber PK; Puigvehí M; Castet F; Lourdusamy V; Montal R; Tabrizian P; Buckstein M; Kim E; Villanueva A; Schwartz M; Llovet JM
    Gastroenterology; 2021 Sep; 161(3):879-898. PubMed ID: 34126063
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Advances in novel systemic therapies for advanced hepatocellular carcinoma.
    Carloni R; Rizzo A; Cusmai A; Palloni A; Federico AD; Marco MD; Massafra R; Fanizzi A; Palmiotti G; Brandi G
    Future Med Chem; 2022 Oct; 14(20):1455-1470. PubMed ID: 35997677
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management of hepatocellular carcinoma patients with portal vein tumor thrombosis: A narrative review.
    Tao ZW; Cheng BQ; Zhou T; Gao YJ
    Hepatobiliary Pancreat Dis Int; 2022 Apr; 21(2):134-144. PubMed ID: 34955380
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Atezolizumab plus bevacizumab versus sorafenib or atezolizumab alone for unresectable hepatocellular carcinoma: A systematic review.
    Ahmed F; Onwumeh-Okwundu J; Yukselen Z; Endaya Coronel MK; Zaidi M; Guntipalli P; Garimella V; Gudapati S; Mezidor MD; Andrews K; Mouchli M; Shahini E
    World J Gastrointest Oncol; 2021 Nov; 13(11):1813-1832. PubMed ID: 34853653
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatocellular carcinoma, novel therapies on the horizon.
    El Dika I; Makki I; Abou-Alfa GK
    Chin Clin Oncol; 2021 Feb; 10(1):12. PubMed ID: 32527116
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Treatment Landscape of Advanced Hepatocellular Carcinoma.
    Wong KM; King GG; Harris WP
    Curr Oncol Rep; 2022 Jul; 24(7):917-927. PubMed ID: 35347594
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatocellular carcinoma review: current treatment, and evidence-based medicine.
    Raza A; Sood GK
    World J Gastroenterol; 2014 Apr; 20(15):4115-27. PubMed ID: 24764650
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New Opportunities to Individualize Frontline Therapy in Advanced Stages of Hepatocellular Carcinoma.
    Gordan JD; Keenan BP; Lim HC; Yarchoan M; Kelley RK
    Drugs; 2023 Aug; 83(12):1091-1109. PubMed ID: 37402062
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Yttrium-90 microsphere radioembolisation for unresectable hepatocellular carcinoma.
    Abdel-Rahman OM; Elsayed Z
    Cochrane Database Syst Rev; 2016 Feb; 2():CD011313. PubMed ID: 26905230
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination therapies plus transarterial chemoembolization in hepatocellular carcinoma: a snapshot of clinical trial progress.
    Brown ZJ; Hewitt DB; Pawlik TM
    Expert Opin Investig Drugs; 2022 Apr; 31(4):379-391. PubMed ID: 34788184
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neoadjuvant systemic therapy for hepatocellular carcinoma.
    Chick RC; Ruff SM; Pawlik TM
    Front Immunol; 2024; 15():1355812. PubMed ID: 38495884
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.